Cost-effectiveness of QuantiFERON® -TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 4, 2010, Pages 471-481

  Deuffic Burban, Sylvie ^a   Atsou, K ^a   Viget, N ^b   Melliez, H ^b   Bouvet, E ^c   Yazdanpanah, Yazdan ^a,b,c  

^a INSERM   (France)

^b CENTRE HOSPITALIER DE TOURCOING   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

Contact investigation; Cost effectiveness analysis; LTBI; QuantiFERON TB test; Tuberculosis disease

Indexed keywords

BCG VACCINE;

ADULT; ARTICLE; BCG VACCINATION; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; FRANCE; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; LIFE EXPECTANCY; LUNG TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; SIMULATION; TUBERCULIN TEST;

EID: 77950305287     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Ferrara G, Losi M, Meacci M, et al. Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2005; 172: 631-635.
2. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: 340-354.
3. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149: 177-184.
4. Haute Autorité de Santé. Test de détection de la production d'interferon gamma pour le diagnostic des infections tuberculeuses. Saint-Denis La Plaine, France: HAS, 2006. http://www. has-sante.fr/portail/ upload/docs/application/pdf/rapport-detection-de-linterferon-gamma.pdf. [French]
5. National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control: London, UK: Royal College of Physicians, 2006.
6. Mazurek G H, Jereb J, Lobue P, Iademarco M F, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR 2005; 54: 49-55.
7. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis 2007; 11: 16-26.
8. Diel R, Nienhaus A, Lange C, Schaberg T. Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J 2006; 28: 35-44.
9. Diel R, Nienhaus A, Loddenkemper R. Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany. Chest 2007; 131: 1424-1434.
10. Kowada A, Takahashi O, Shimbo T, Ohde S, Tokuda Y, Fukui T. Cost effectiveness of interferon-gamma release assay for tuberculosis contact screening in Japan. Mol Diagn Ther 2008; 12: 235-251.
11. Marra F, Marra C A, Sadatsafavi M, et al. Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts. Int J Tuberc Lung Dis 2008; 12: 1414-1424.
12. Weinstein M C, Siegel J E, Gold M R, Kamlet M S, Russell L B. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276: 1253-1258.
13. Reichler M R, Reves R, Bur S, et al. Evaluation of investigations conducted to detect and prevent transmission of tuberculosis. JAMA 2002; 287: 991-995.
14. Martinez Alfaro E, Solera J, Serna E, Cuenca D, et al. [Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis]. Med Clin (Barc) 1998; 111: 401-404. [Spanish]
15. LoBue P A, Moser K S. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003; 168: 443-447.
16. Menzies D, Dion M J, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004; 170: 445-449.
17. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008; 149: 689-697.
18. Page K R, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006; 166: 1863-1870.
19. Vynnycky E, Fine P E. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of re-infection. Epidemiol Infect 1997; 119: 183-201.
20. Vynnycky E, Fine P E. Lifetime risks, incubation period and serial interval of tuberculosis. Am J Epidemiol 2000; 152: 247-263.
21. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR (RR-6): 2000; 49: 1-71.
22. Millard P S, Wilcosky T C, Reade-Christopher S J, Weber D J. Isoniazid-related fatal hepatitis. West J Med 1996; 164: 486-491.
23. Salpeter S R. Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. West J Med 1993; 159: 560-564.
24. Salpeter S R, Sanders G D, Salpeter E E, Owens D K. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997; 127: 1051-1061.
25. Moulding T S, Redeker A G, Kanel G C. Twenty isoniazida ssociated deaths in one state. Am Rev Respir Dis 1989; 140: 700-705.
26. Snider D E, Jr, Caras G J. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992; 145: 494-497.
27. Jindani A, Nunn A J, Enarson D A. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364: 1244-1251.
28. Nolan C M, Goldberg S V, Buskin S E. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. Jama 1999; 281: 1014-1018.
29. Teleman M D, Chee C B, Earnest A, Wang Y T. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int J Tuberc Lung Dis 2002; 6: 699-705.
30. Direction Générale de la Santé. Avis du Conseil Supérieur d'Hygiène Publique de France. Section maladies transmissibles. Relatif au traitement de la tuberculose-infection. 14 mars 2003. Paris, France: Direction Générale de la Santé, 2003. http://www. sante.gouv.fr/htm/dossiers/cshpf/a-mt-140303-tbc-traitement. pdf. [French]
31. Haute Autorité de Santé. Active tuberculosis. Guide for doctors: long-term conditions. Saint-Denis La Plaine, France: HAS, 2007. http: //www.has-sante.fr/portail/upload/docs/application/ pdf/gm-tuberculoseen-web. pdf.
32. Institut national d́tudes démographiques. Mortality rates in 2005. Paris, France: INED, 2009. http: //www.ined.fr/en/pop-figures/france/ deaths-causes-mortality/mortality-rates-sex-age/.
33. Mark D B, Hlatky M A, Califf R M, et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418-1424.
34. Bruhl D L, Paty M C, Antoine D, Bessette D. Recent changes in tuberculosis control and BCG vaccination policy in France. Euro Surveill 2007; 12: 3268.
35. National Tuberculosis Controllers Association, Centers for Disease Control and Prevention. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC. MMWR 2005; 54 (RR-15): 1-62.